ATM D1682H

CI-VAR-00000428Explore in graph →NP_000042.3:p.Asp1682HisNM_000051.3:c.5044G>CClinVar 3026 CIViC 1168 rs121434217

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Lymphocytic Leukemia1
ATM D1682H	Doxorubicin	Predictive	D	Supports Resistance	3	accepted	EID2845 Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1682H variant on ATM expression was tested by weste… (full text at CIViC) PMID 23585524 · Navrkalova et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
3026	Uncertain significance	criteria provided, single submitter	1	T-cell prolymphocytic leukemia; Hereditary cancer-predisposing syndrome	germline/somatic	2	Mar 18, 2025	clinvar